Balanced news tone
News Sentiment
4507 sentiment intelligence
Shionogi & Co., Ltd. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
51
Balanced news tone
19 relevant articles
News tone and price action are not far from neutral.
77/100 classification confidence.
directly relevant articles
high-authority source matches
-1.3% over one week, +2.1% over four weeks, trend inactive, and near fair-value range.
Shionogi & Co (4507) Q1 2026 earnings summary
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Primary event
Market update
77/100 classification
One-week reaction
-1.3%
Price digesting
Trend fit
Trend inactive
2.1% over four weeks
Fair value
17.8%
Near fair-value range
Sentiment Mix
Positive, neutral, negative
Positive
3
Neutral
14
Negative
2
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Quartr
Direct company coverage
Shionogi & Co (4507) Q1 2026 earnings summary
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 06 Jul 2026 19:44
- Source
- Quartr
ad-hoc-news.de
Direct company coverage
The Xocova from Shionogi - COVID-19 antiviral that targets Japan’s home market first
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 05 Jul 2026 02:51
- Source
- ad-hoc-news.de
ad-hoc-news.de
Direct company coverage
Shionogi stock holds the line. Focus stays on the company
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 04 Jul 2026 14:44
- Source
- ad-hoc-news.de
simplywall.st
Direct company coverage
Shionogi’s Olorofim Phase 3 Success And XOCOVA Expansion Might Change The Case For Investing In Shionogi (TSE:4507)
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 28 Jun 2026 07:00
- Source
- simplywall.st
simplywall.st
Direct company coverage
Shionogi (TSE:4507) Infectious Disease Progress Keeps Valuation Questions In Play
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Jun 2026 07:00
- Source
- simplywall.st
Seeking Alpha
Direct company coverage
Shionogi & Co., Ltd. (SGIOY) Shareholder/Analyst Call - Slideshow (OTCMKTS:SGIOY) 2026-06-25
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 25 Jun 2026 07:00
- Source
- Seeking Alpha
Market source
Direct company coverage
Shionogi (TSE:4507) Valuation Check As XOCOVA Wins First US FDA Approval For COVID 19 Post Exposure Prophylaxis
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 10 Jun 2026 07:00
- Source
- Market source
simplywall.st
Direct company coverage
The Shionogi & Co., Ltd. (TSE:4507) Annual Results Are Out And Analysts Have Published New Forecasts
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- simplywall.st
Shionogi Inc.
Direct company coverage
Shionogi Selected as a “DX Stock 2026”| 塩野義製薬
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Apr 2026 07:00
- Source
- Shionogi Inc.
Pharmaceutical Technology
Direct company coverage
Shionogi expands ViiV Healthcare stake by $2.13bn as Pfizer sells up
- Tone
- Positive 66/100
- Event
- Deals and strategy
- Published
- 20 Jan 2026 08:00
- Source
- Pharmaceutical Technology
Reuters
Direct company coverage
Pfizer to exit ViiV Healthcare in $1.9 billion deal as Shionogi doubles stake
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 19 Jan 2026 08:00
- Source
- Reuters
marketscreener.com
Direct company coverage
Shionogi & Co., Ltd. acquired 54.84% stake in Torii Pharmaceutical Co., Ltd. from Japan Tobacco Inc..
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 31 Aug 2025 07:00
- Source
- marketscreener.com
BioWorld News
Direct company coverage
Shionogi to acquire Japan Tobacco pharma companies for $1.1B
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 May 2025 07:00
- Source
- BioWorld News
Reuters
Direct company coverage
Drugmaker Shionogi to buy Japan Tobacco's unit Torii Pharmaceutical for $1 billion
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 07 May 2025 07:00
- Source
- Reuters
Reuters
Direct company coverage
Shionogi sinks in Tokyo trade after panel again delays COVID pill approval
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 20 Jul 2022 07:00
- Source
- Reuters
WSJ
Direct company coverage
Shionogi Shares Slump After Japan Panel Rejects Emergency Approval for its Covid-19 Drug
- Tone
- Negative 34/100
- Event
- Regulatory and legal
- Published
- 20 Jul 2022 07:00
- Source
- WSJ
朝日新聞
Direct company coverage
Shionogi says continuing Vietnam COVID projects after partner scandals
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Jun 2022 07:00
- Source
- 朝日新聞
Fortune
Direct company coverage
Shionogi COVID pill: Investors flee drugmaker on news of birth defect risk
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 13 Apr 2022 07:00
- Source
- Fortune
MarketBeat
Direct company coverage
Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) Stock Price, News & Analysis
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 24 Sep 2019 21:36
- Source
- MarketBeat